---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-046662"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2022-02-18T23:59:59+00:00"
generated_at: "2026-06-27T06:37:53.327100+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma enters $20M SVB loan facility with tranche A of $10M available immediately

## Summary
- Tranche A of $10M funded at closing; two additional tranches up to $5M each contingent on CUE-101 data and equity proceeds.
- Interest rate: prime plus 2.25% (floor 5.5%); repayment begins June 2023 or Dec 2023 if tranche B advanced; maturity Dec 2025.
- Prepayment premium: 3% within 1yr, 2% 1-2yr, 1% after 2yr; final payment fee 5% of original principal.
- Secured by substantially all assets except IP (negative pledge); requires cash at SVB equal to lesser of all cash or 110% of obligations.
- Standard events of default; default triggers 3% rate increase and acceleration of all obligations.

## SEC filing metadata
- accession: 0001193125-22-046662
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2022-02-18T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000119312522046662/0001193125-22-046662-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000119312522046662/d302848d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-046662
- JSON: https://secwatch.observer/filing/0001193125-22-046662.json
- Plain text: https://secwatch.observer/filing/0001193125-22-046662.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.